Back HIV/AIDS HIV/AIDS Topics HIV Treatment FDA Updates Etravirine (Intelence) Label with Additional Information on Drug Interactions

FDA Updates Etravirine (Intelence) Label with Additional Information on Drug Interactions

alt

The U.S. Food and Drug Administration (FDA) last week announced that the product label for the next-generation NNRTI etravirine (Intelence) has been updated to include new information about drug-drug interactions with the boosted protease inhibitor lopinavir/ritonavir (Kaletra), the antifungal agents fluconazole (Diflucan) and voriconazole (VFEND), and the anti-clotting medication clopidogrel (Plavix).

Below is the text of the recent FDA press release describing the changes.

Intelence (Etravirine) Label Revised to Include New Drug-Drug Interaction Information

FDA recently updated the Intelence (etravirine) label to include drug-drug interaction information between etravirine and fluconazole, voriconazole, lopinavir/ritonavir tablets and clopidogrel. The major changes to Section 7 Drug Interactions are summarized below.

In addition the magnitude of the interaction for etravirine in the presence of fluconazole, voriconazole and lopinavir/ritonavir tablets can be found in section 12.3 Pharmacokinetics.

Etravirine - fluconazole and voriconazole: Co-administration of etravirine and fluconazole or voriconazole significantly increased etravirine exposures. The amount of safety data at these increased etravirine exposures is limited; therefore, etravirine and fluconazole or voriconazole should be co-adminstered with caution. No dose adjustments of Intelence, fluconazole or voriconazole is needed.

Etravirine - lopinavir/ritonavir tablets: Intelence and Kaletra (lopinavir/ritonavir) tablets can be co-administered without dose adjustment

Etravirine - clopidogrel: Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Intelence. Alternative to clopidogrel should be considered.

Please refer to http://www.accessdata.fda to view the complete updated label.

Etravirine is a Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) made by Tibotec Therapeutics.

3/16/10

Sources

R Klein and K Struble (Food and Drug Administration). Intelence (Etravirine) Label Revised to Include New Drug-Drug Interaction Information. HIV/AIDS Update. March 11, 2010.

Food and Drug Administration. Intelence (etravirine) label revised to include new drug-drug interaction information. Press release. March 11, 2010.